Gilead (GILD, $68.29) beats Q2 earnings and sales expectations
Gilead Sciences’ quarterly adjusted earnings came in at $1.87 per share for the quarter ended June, surpassing Zacks Consensus Estimate of $1.76 per share. It was $1.11 per share in the year-ago quarter.
The biopharma company has exceeded consensus EPS estimates four times over the last four quarters.
Gilead’s revenues were $6.22 billion, beating the Zacks Consensus Estimate by 1.14%. Sales were $5.14 billion in the year-ago period. The company beat consensus revenue estimates three times over the last four quarters.
GILD's RSI Indicator recovers from overbought zone
The 10-day RSI Oscillator for GILD moved out of overbought territory on April 22, 2022. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 instances where the indicator moved out of the overbought zone. In 16 of the 23 cases the stock moved lower in the days that followed. This puts the odds of a move down at 70%.
Current price $62.37 crossed the resistance line at $60.93 and is trading between $77.90 resistance and $60.93 resistance lines. Throughout the month of 04/12/22 - 05/13/22, the price experienced a +1% Uptrend. During the week of 05/06/22 - 05/13/22, the stock enjoyed a +2% Uptrend growth.
The Stochastic Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Momentum Indicator moved above the 0 level on May 12, 2022. You may want to consider a long position or call options on GILD as a result. In 60 of 115 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 52%.
The Moving Average Convergence Divergence (MACD) for GILD just turned positive on May 13, 2022. Looking at past instances where GILD's MACD turned positive, the stock continued to rise in 31 of 51 cases over the following month. The odds of a continued upward trend are 61%.
GILD moved above its 50-day Moving Average on May 02, 2022 date and that indicates a change from a downward trend to an upward trend.
The 10-day Moving Average for GILD crossed bullishly above the 50-day moving average on April 12, 2022. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 39%.
Following a +0.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 152 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
GILD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 103 of 214 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 48%.
Tickeron has a negative outlook on this ticker and predicts a further decline by more than 4.00% within the next month with a likelihood of 76%. During the last month, the daily ratio of advancing to declining volumes was 1 to 1.03.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock slightly worse than average.
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.926) is normal, around the industry mean (6.847). P/E Ratio (17.422) is within average values for comparable stocks, (85.171). Projected Growth (PEG Ratio) (0.533) is also within normal values, averaging (3.164). GILD has a moderately high Dividend Yield (0.046) as compared to the industry average of (0.026). P/S Ratio (2.865) is also within normal values, averaging (3.807).
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
The average market capitalization across the Pharmaceuticals: Major Industry is 77.6B. The market cap for tickers in the group ranges from 226K to 465.4B. JNJ holds the highest valuation in this group at 465.4B. The lowest valued company is NEWG at 226K.
The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -1.49%. For the same Industry, the average monthly price growth was -5.38%, and the average quarterly price growth was -8.71%. GIFOF experienced the highest price growth at 17.34%, while DCHPF experienced the biggest fall at -28.83%.
The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -5.23%. For the same stocks of the Industry, the average monthly volume growth was 12.33% and the average quarterly volume growth was -2.15%
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Stocks in the group have a Positive Outlook today, backed by the Volume Indicator. Tickeron has a positive outlook on this group and predicts a further increase by more than 4.00% within the next month with a likelihood of 37%. During the last month, the daily ratio of advancing to declining volumes was 1.07 to 1.
10 stocks in the group of tickers confirmed the positive outlook based on the RSI indicator with average odds of 87%.
The most notable companies in this group are Novavax (NASDAQ:NVAX), BioCryst Pharmaceuticals (NASDAQ:BCRX), Cel-Sci Corp (ASE:CVM).
The average market capitalization across the group is 762.5M. The market cap for tickers in the group ranges from 18.6M to 4.1B. NVAX holds the highest valuation in this group at 4.1B. The lowest valued company is IDRA at 18.6M.
The average weekly price growth across all stocks in the group was -8.1%. For the same group, the average monthly price growth was -27.67%, and the average quarterly price growth was -58%. AGEN experienced the highest price growth at -2.4%, while IDRA experienced the biggest fall at -16.58%.
- 5/14/22 4:23 AM: Idera Pharmaceuticals (IDRA, $0.35) is a top weekly loser for penny stocks, falling -16.58%
- 5/12/22 5:38 AM: Pluristem Therapeutics (PSTI, $1.43) is a top weekly loser for penny stocks, falling -15.88%
- 5/10/22 5:36 AM: Genetic Technologies (GENE, $1.32) is a top weekly loser for penny stocks, falling -16.82%
The average weekly volume growth across all stocks in the group was 25.16%. For the same stocks of the group, the average monthly volume growth was 46.59% and the average quarterly volume growth was 36.43%
- 5/14/22 4:16 AM: The volume for Compugen stock increased for four consecutive days, resulting in a record-breaking daily growth of 84% of the 65-Day Volume Moving Average
- 4/20/22 8:52 AM: The volume for Idera Pharmaceuticals stock increased for one day, resulting in a record-breaking daily growth of 349% of the 65-Day Volume Moving Average
- 3/19/22 4:43 AM: The volume for Agenus stock increased for one day, resulting in a record-breaking daily growth of 249% of the 65-Day Volume Moving Average
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows